134 related articles for article (PubMed ID: 37149430)
21. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
22. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
23. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
25. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.
Al Hussein Al Awamlh B; Ballman KV; Ma X; Hu JC; Shoag JE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):714-717. PubMed ID: 32661433
[TBL] [Abstract][Full Text] [Related]
26. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
Liu Y; Hall IJ; Filson C; Howard DH
Urol Oncol; 2021 Jul; 39(7):432.e1-432.e10. PubMed ID: 33308973
[TBL] [Abstract][Full Text] [Related]
27. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
28. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
30. Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.
Holmes JA; Wang AZ; Hoffman KE; Hendrix LH; Rosenman JG; Carpenter WR; Godley PA; Chen RC
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):88-94. PubMed ID: 22300560
[TBL] [Abstract][Full Text] [Related]
31. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
32. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F;
Eur Urol; 2011 Jan; 59(1):61-71. PubMed ID: 21056534
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis.
Sayyid RK; Benton JZ; Reed WC; Woodruff P; Terris MK; Wallis CJD; Klaassen Z
World J Urol; 2023 Jan; 41(1):93-99. PubMed ID: 36472651
[TBL] [Abstract][Full Text] [Related]
34. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
35. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
36. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
37. Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance.
Marra G; Soeterik T; Oreggia D; Tourinho-Barbosa R; Moschini M; Filippini C; van Melick HHE; van den Bergh RCN; Gontero P; Cathala N; Macek P; Sanchez-Salas R; Cathelineau X
Eur Urol Focus; 2022 May; 8(3):701-709. PubMed ID: 33926838
[TBL] [Abstract][Full Text] [Related]
38. A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer.
Kim SP; Tilburt JC; Shah ND; Yu JB; Konety B; Nguyen PL; Abouassaly R; Williams SB; Gross CP
Clin Genitourin Cancer; 2019 Jun; 17(3):e472-e481. PubMed ID: 30827923
[TBL] [Abstract][Full Text] [Related]
39. Active surveillance: the Canadian experience with an "inclusive approach".
Klotz L
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):234-41. PubMed ID: 23271779
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
